Ultragenyx Pharmaceutical (NASDAQ:RARE) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a research report report published on Wednesday, Benzinga reports. The firm currently has a $115.00 price target on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the company. The Goldman Sachs Group raised Ultragenyx Pharmaceutical from […]
More Stories
Parks! America, Inc. (OTCMKTS:PRKA) Short Interest Down 35.3% in September
Parks! America, Inc. (OTCMKTS:PRKA – Get Free Report) was the target of a large decline in short interest in the...
Dimensional Global ex US Core Fixed Income ETF (NASDAQ:DFGX) Short Interest Up 74.1% in September
Dimensional Global ex US Core Fixed Income ETF (NASDAQ:DFGX – Get Free Report) saw a significant growth in short interest...
iShares iBonds Dec 2031 Term Treasury ETF (NASDAQ:IBTL) Short Interest Update
iShares iBonds Dec 2031 Term Treasury ETF (NASDAQ:IBTL – Get Free Report) was the recipient of a significant increase in...
Leafly Holdings, Inc. (NASDAQ:LFLYW) Sees Significant Decrease in Short Interest
Leafly Holdings, Inc. (NASDAQ:LFLYW – Get Free Report) was the target of a large decline in short interest during the...
Eaton Vance Short Duration Income ETF (NASDAQ:EVSD) Sees Significant Increase in Short Interest
Eaton Vance Short Duration Income ETF (NASDAQ:EVSD – Get Free Report) saw a large growth in short interest in September....
Impala Platinum Holdings Limited (OTCMKTS:IMPUY) Short Interest Update
Impala Platinum Holdings Limited (OTCMKTS:IMPUY – Get Free Report) was the recipient of a large increase in short interest during...